Navigation Links
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
Date:2/29/2008

WILMINGTON, Del., Feb. 29 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.

MDD affects 15 million American adults -- between 5 and 8 percent of the population each year -- and today it is often treated with generic or branded antidepressants.(1) Studies have shown that at least one-third of patients with MDD treated with antidepressants fail to achieve a satisfactory response.(2) The American Psychiatric Association Practice Guidelines recommend switching to a medication in another class when two medications from the same class have proven ineffective.(3) AstraZeneca has investigated the use of SEROQUEL XR, an atypical antipsychotic, in the treatment of MDD, aiming to develop another potential treatment option, including treatment for patients who have failed or had an inadequate response to another antidepressant therapy.

The MDD submission is based on seven Phase III, placebo-controlled studies that assessed the efficacy and safety of once-daily treatment with SEROQUEL XR in patients diagnosed with MDD. Studies 1, 2, 3, and 4 were acute monotherapy studies involving 2,116 patients; Studies 6 and 7 were acute adjunct therapy studies (with ongoing antidepressant therapy) involving 939 patients who had an inadequate response to an antidepressant therapy; and Study 5 was a longer-term (up to 78 weeks) monotherapy maintenance study involving 1,854 patients. The acute studies included in this submission used the Montgomery-Asberg Depression Rating Scale (MADRS)* as the primary assessment of depression symptoms. In the longer-term study (Study 5), the primary assessment was time to a depressed event using c
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pediatric Asthma Programs Featuring PARI Pharmas eFlow Acquired by AstraZeneca
2. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
3. AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease
4. Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development
5. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
6. AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
7. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. Cephalon Submits Supplemental New Drug Application for FENTORA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 05, 2015 Research ... has announced the addition of the ... to their offering. Macromolecules which ... undergo separation or are broken into smaller ... products. This separation requires various advanced systems ...
(Date:5/5/2015)... 5, 2015 Psyche Systems Corporation and Luminate ... a first-of-its-kind platform that helps labs comply with new ... transforms the way patients engage with these results, and ... provides a HIPAA-compliant digital platform that gives labs ... understand their lab results, and uniquely connects labs, physicians, ...
(Date:5/5/2015)... , May 5, 2015  Tikcro Technologies Ltd. ... approved to continue trading on OTCQB  Marketplace, the ... OTCQB Marketplace allows for a continuous public market ... can have real-time quotes and market information on ... The OTCQB Marketplace includes U.S. and international companies ...
(Date:5/5/2015)... The Academy of Model Aeronautics is pleased to ... Gov. Mike Pence, has declared August 15, 2015, as ... Family Fest and aviation themed Motorcycle Rally in Muncie, ... Warrior Project. , National Model Aviation Day has been ... organization for model aviation—to celebrate the history of model ...
Breaking Biology Technology:Global Separation Systems Market in Biotechnology 2015-2019 - Trends and Forecasts for the $28 Billion Market 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 3Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2State of Indiana proclaims August 15 as Model Aviation Day 2
... is launching Prospera , an online personnel ... 13,000 human resources professionals, the company announced Tuesday. The ... of concern for human resources staffs: plan, staff, compensate, ... affect a company's bottom line; then it illustrates, step-by-step, ...
... of Boston will become the new majority owner of ... to mortgage lenders. , , Spectrum on Wednesday ... of Mortgagebot. , ,Following the transaction, Michael Kennealy and ... directors. Terms of the transaction were not disclosed. , ...
... the financial technology subsidiary of Marshall & Ilsley Corp., ... The company will continue to operate under the name ... Metavante , with existing management continuing in their positions, ... not disclosed. , ,LINK2GOV provides customized online phone ...
Cached Biology Technology:J.J. Keller, Modine Manufacturing, Gustave A. Larson Co., Esker, Firstlogic, Software One 2Boston equity firm becomes majority owner of Cedarburg-based Mortgagebot 2Metavante acquiring LINK2Gov 2
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... 23, 2015, after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... A new way of delivering corrective genes with a ... treatments of hereditary diseases of the heart, University of ... to successfully reverse symptoms in mice with a form ... tested the virus-based delivery method in monkeys and found ...
... to strike the Indonesian island of Java - was to ... Under the leadership of Dr. Raymond Vanholder, the Task Force ... from Médecins Sans Frontières (MSF). , The two Task ... participated in the Kashmir-Pakistan intervention in November 2005), and Mr. ...
... Ltd and the Institute for Eye Research have received ... an antibacterial extended-wear contact lens. , The ASX-listed company ... at the Centre for Marine Biofouling and Bioinnovation. ... the safety performance of an antibacterial contact lens to ...
Cached Biology News:UF scientists test improved gene therapy method for hereditary heart conditions 2UF scientists test improved gene therapy method for hereditary heart conditions 3UF scientists test improved gene therapy method for hereditary heart conditions 4Indonesia - disaster relief aid in action 2First human trial of antibacterial contact lens 2